Merck & Co. has secured the top spot for pharmaceutical R&D investment again in 2024 after topping the list last year by a wide margin. While continuing to channel resources into expanding Keytruda’s oncology indications (with a 2025 patent cliff looming), Merck is also expanding beyond oncology. In cardiovascular, it launched Winrevair for pulmonary arterial hypertension with $419 million in sales. Vaccine efforts progressed with CAPVAXIVE, recommended by the CDC’s ACIP for…
